Skip to main content

Table 4 Attributes and levels of treatments for patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole

From: Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments

Attributes

Levels

Progression free survival (PFS)

2, 8, 14 months

Anemia

0, 3, 6 %

Pneumonitis

0, 2, 4 %

Monthly cost

0, US$3030.3, US$6060.6a

  1. aThe exchange rate was approximately 33 Baht per US$1(Bank of Thailand 2014)